Drug Information

General Information
Drug ID
DR01395
Drug Name
Triprolidine
Synonyms
Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride
Drug Type
Small molecular drug
Indication Allergic rhinitis [ICD11: CA08.0] Approved [1]
Therapeutic Class
Antiallergic Agents
Structure
3D MOL 2D MOL
Formula
C19H22N2
Canonical SMILES
CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3
InChI
InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
InChIKey
CBEQULMOCCWAQT-WOJGMQOQSA-N
CAS Number
CAS 486-12-4
Pharmaceutical Properties Molecular Weight 278.4 Topological Polar Surface Area 16.1
Heavy Atom Count 21 Rotatable Bond Count 4
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 2
XLogP
3.9
PubChem CID
5282443
PubChem SID
7980840 , 8077587 , 11038508 , 14897473 , 17448291 , 26751829 , 39315888 , 46505403 , 47291040 , 47440150 , 47736373 , 47736374 , 47885310 , 47885311 , 48110356 , 48334387 , 49698410 , 49855442 , 50104523 , 50104524 , 50104525 , 57309729 , 75497893 , 85209605 , 85788432 , 90341007 , 92308937 , 93166727 , 96025331 , 103223987 , 104133962 , 113857221 , 124610340 , 124886935 , 124886936 , 134338323 , 134975511 , 135651281 , 137002512 , 138314072 , 140229550 , 144204470 , 160963773 , 170464931 , 172820007 , 175267951 , 176483998 , 179113821 , 181753769 , 181855806
ChEBI ID
CHEBI:84116
TTD Drug ID
D0E8CI
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Triprolidine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos. 2007 Aug;35(8):1341-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.